The amyloid precursor protein: beyond amyloid.
Zheng H, Koo EH. · 2006
Read The amyloid precursor protein: beyond amyloid. by Zheng H, Koo EH. (2006) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc1538601.txt.
Introduction
One protein sits at the heart of Alzheimer's disease. Zheng and Koo reviewed its wider life in 2006. The amyloid precursor protein, APP, is cut to make the beta-amyloid pieces that form brain plaques. Faults in its gene cause some early, inherited forms of the disease.
Yet APP does more than yield plaques. Lab studies assign it roles in cell growth, sticking, and signaling. Fly and mouse mutants, with the gene added or removed, show it matters for normal brain work. Zheng urges the field to study the whole protein, not just its toxic fragment.
Catalog record
| CREATOR | Zheng H, Koo EH. |
|---|---|
| YEAR | 2006 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 66 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The amyloid precursor protein: beyond amyloid By Hui Zheng, Edward H Koo Published in: Molecular Neurodegeneration DOI: 10.1186/1750-1326-1-5 ABSTRACT Abstract The amyloid precursor protein (APP) takes a central position in Alzheimer's disease (AD) pathogenesis: APP processing generates the β-amyloid (Aβ) peptides, which are deposited as the amyloid plaques in brains of AD individuals; Point mutations and duplications of APP are causal for a subset of early onset of familial Alzheimer's disease (FAD). Not surprisingly, the production and pathogenic effect of Aβ has been the central focus in AD field. Nevertheless, the biological properties of APP have also been the subject of intense investigation since its identification nearly 20 years ago as it demonstrates a number of interesting putative physiological roles. Several attractive models of APP function have been put forward recently based on in vitro biochemical studies. Genetic analyses of gain- and loss-of-function mutants in Drosophila and mouse have also revealed important insights into its biological activities in vivo. This article will review the current understanding of APP physiological functions. BACKGROUND Alzheimer's disease (AD) is the most common cause of dementia occurring in the elderly. It is characterized pathologically by the deposition of β-amyloid plaques, the accumulation of neurofibrillary tangles and loss of neurons and synapses in selected areas of the brain. The β-amyloid plaques are extracellular deposits of heterogeneous substances of which the major components are 40 to 42 amino acid peptides referred to as β-amyloid peptides (Aβ) that are derived by proteolytic cleavages of the amyloid precursor protein (APP). Liberation of Aβ from APP requires the action of β- and γ-secretases which process APP at amino-terminus and carboxyl-terminus of the Aβ sequence, respectively (reviewed in [1,2]). Approximately 5–10% of AD cases are familial and cosegregate with autosomal dominant inheritance of mutations in APP [3] and two homologous molecules, presenilin 1 (PS1) [4] and presenilin 2 (PS2) [5] (up-to-date genetic mutations can be found at http://www.alzforum.org). PS1 or PS2 is a necessary component of the high molecular weight complex indispensable for γ-secretase processing of APP. The familial AD (FAD) mutations in the presenilin genes are known to subtly alter the γ-secretase activity to perturb APP proteolysis (reviewed in [6]). This biochemical and genetic evidence places APP and its processing steps in a central position in AD research. This review focuses on the physiological properties of APP. We start with a general overview of APP, including its family members, expression patterns and processing characteristics. Because APP consists of multiple structural and functional domains, we will focus our review by addressing the properties of the APP ectodomain and the intracellular domain. Finally, we provide an update on the current knowledge concerning the APP function in vivo. Understanding the biology of APP is not only interesting from an intellectual point of view, but also of immediate relevance to AD pathogenesis. Because Aβ is generated as part of the normal APP processing, deregulation of Aβ production is expected to simultaneously affect other APP processing metabolites and perhaps APP regulated pathways. As such, perturbation of normal APP physiology may contribute to AD pathogenesis in an Aβ dependent or independent manner. The pathophysiology of Aβ, which has been the focal point of AD research for the past two decades, has been extensively discussed and is beyond the scope of this review. I. APP: an overview a) The APP family APP is a member of a family of conserved type I membrane proteins including APL-1 in C. elegans [7], APPL in Drosophila [8,9] and APP [10,11], APP like protein 1 (APLP1) [12] and 2 (APLP2) [13,14] in mammals (reviewed in [15]) (Figure 1). These proteins share several conserved motifs, including the E1 and E2 domains in the extracellular sequences and the intracellular domain, the latter exhibits the highest sequence identity. Of interest, the Aβ peptide domain is not conserved and is unique to APP. However, the mammalian APP homologs play redundant activities in vivo (discussed in "The in vivo Function of APP"). The functional conservation of the APP across species is documented by the partial rescue of the Drosophila APPL null behavioral phenotype by human APP [16]. These observations indicate that the conserved motifs, rather than the Aβ sequence, likely underlie the conserved physiological functions among the APP species. [Figure: Amino acid sequence alignment of C. elegans APL-1, Drosophila APPL and human APP, APLP1 and APLP2. Identical sequences are shaded in green and conserved changes in light blue. The E1 and E2 domains are shown in purple and orange underlines respectively. Yellow bracket denotes the transmembrane domain, the Aβ sequences is outlined within the red bracket, and the Thr668 residue and the YENPTY sequence are marked by the asterisk and filled squares underneath the sequences respectively.] b) APP expression Mammalian APP family of proteins is abundantly expressed in the brain. Similar to Drosophila APPL [17], APLP1 expression is restricted to neurons [18]. However, although highly enriched in the brain, APP and APLP2 can be detected in most other tissues as well. The human APP gene, located on the long arm of chromosome 21, spans approximately 240 kb and contains at least 18 exons [19,20]. Alternative splicing generates APP mRNAs encoding several isoforms that range from 365 to 770 amino acid residues. The major Aβ peptide encoding proteins are 695, 751, and 770 amino acids (referred to as APP695, APP751 and APP770). APP751 and APP770 contain a domain homologous to the Kunitz-type serine protease inhibitors (KPI) in the extracellular sequences, and these isoforms are expressed in most tissues examined. APP695 isoform lacks the KPI domain and is predominately expressed in neurons [21]. The reason and functional significance for this apparent tissue-specific alternative splicing is poorly understood. c) APP processing APP undergoes constitutive secretory pathway and is post-translationally modified in route by N- and O-glycosylation, phosphorylation and tyrosine sulphation (reviewed in [2]). Full-length APP is sequentially processed by at least three proteinases termed α-, β- and γ-secretases (Figure 2). Cleavage by α-secretase or β-secretase within the luminal/extracellular domain results in the shedding of nearly the entire ectodomain to yield large soluble APP derivatives (called APPsα and APPsβ respectively) and generation of membrane-tethered α- or β-carboxyl-terminal fragments (CTFs). The major neuronal β-secretase is a transmembrane aspartyl protease, termed BACE1 (β-site APP cleaving enzyme) [22-24]. Several zinc metallopreoteinases, including TACE/ADAM17, ADAM9, ADAM10 and MDC-9, and an aspartyl protease BACE2 can cleave APP at the α-secretase site located within the Aβ domain (Figure 2) (reviewed in [25]), essentially precluding the generation of intact Aβ. Following the extracellular cleavages, γ-secretase processes APP at the carboxyl-terminus of Aβ, producing either a 3 kDa product (p3 in combination with the α-secretase) or Aβ (in concert with BACE1 cleavage), respectively, and the APP intracellular domain (AICD). The γ-secretase activity is primarily executed by a high molecular weight complex containing at least presenilin, nicastrin, anterior pharynx defective (APH1) and presenilin enhancer (PEN2) (reviewed in [6,26]). However, the list of γ-secretase components may be expanding as other new molecules are being identified [27]. These processing events occur in various organelles and also on cell surface. In neurons, APP is anterogradely transported along the axons and is proteolytically processed during transit ([28-30], also discussed below). In non-neuronal cells, APP that reaches to plasma membrane is internalized within minutes